UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
FORM 8-K
Current Report Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 22, 2003
Date of Filing: May 22, 2003
Lynx Therapeutics, Inc.
Delaware
(State or other jurisdiction of incorporation)
| 0-22570 (Commission File No.) |
94-3161073 (IRS Employer Identification No.) |
25861 Industrial Blvd.
Hayward, California 94545
(Address of principal executive offices and zip code)
Registrant’s telephone number, including area code: (510) 670-9300
| Item 5. Other Events and Required FD Disclosures | ||||||||
| Item 7. Financial Statements, Pro Forma Financial Information and Exhibits | ||||||||
| SIGNATURE | ||||||||
| EXHIBIT 99.1 | ||||||||
Item 5. Other Events and Required FD Disclosure
On May 22, 2003, Lynx Therapeutics, Inc. issued a press release announcing its transfer to the Nasdaq SmallCap Market. A copy of such press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Item 7. Financial Statements, Pro Forma Financial Information and Exhibits
(c) Exhibits
| 99.1 | Press release entitled “Lynx Announces Transfer to the Nasdaq SmallCap Market,” dated May 22, 2003. |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| LYNX THERAPEUTICS, INC. | ||||
| Dated: May 22, 2003 | By: | /s/ Edward C. Albini
Edward C. Albini Chief Financial Officer (Principal Financial and Accounting Officer) |
||
INDEX TO EXHIBITS
| 99.1 | Press release entitled “Lynx Announces Transfer to the Nasdaq SmallCap Market,” dated May 22, 2003. |